NYSE$NSPR
InspireMD Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported increased revenue driven by CGuard EPS and increased gross profit due to distributor settlement impact, with operating expenses rising due to FDA study and market expansion.
InspireMD reported a significant increase in revenue for Q4 2021, driven by strong growth in CGuard EPS sales. The company's gross profit improved compared to the previous year. Operating expenses also increased due to investments in a U.S. FDA study and market expansion.
- Revenue increased by 773.8% to $1,380,000 compared to Q4 2020.
- CGuard EPS revenue increased by 87.5% to $1,291,000 compared to Q4 2020.
- Gross profit increased to $294,000 compared to a gross loss of $390,000 in Q4 2020.
- Net loss totaled $4,097,000, or $0.53 per share, compared to a net loss of $3,853,000, or $1.52 per share, in Q4 2020.
Headline financials
Revenue & EPS history
InspireMD · Revenue · Quarterly
$1.38M
Revenue by segment
InspireMD · $1.29M total across 1 segment · Q4 2021
- CGuard EPS$1.29M+87.4%100.0%
Forward guidance
InspireMD anticipates growth of CGuard, pipeline development, and evidence demonstrating CGuard's superiority in clinical performance.
Tailwinds
- Anticipating growth of CGuard
- Continuing pipeline development
- Advancing the growing body of evidence demonstrating CGuard’s superiority in clinical performance amongst all other stent options and surgery
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-3.7%
Avg return
Earnings day
-7.1%
Avg return
5 days after
-12.5%
Avg return
30 days after
32%
19 / 60 earnings
Positive
+15.4%
Q4 2014
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +0.0% | — | |
| Q4 2025 | +0.0% | -2.8% | -24.6% | |
| Q3 2025 | -7.0% | -21.0% | -16.2% | |
| Q1 2025 | +0.0% | -9.2% | -3.8% | |
| Q4 2024 | +0.7% | +0.4% | -8.2% | |
| Q3 2024 | +2.0% | +2.8% | +25.6% | |
| Q2 2024 | -3.4% | -3.4% | -7.4% | |
| Q1 2024 | -4.2% | -4.2% | +8.3% | |
| Q4 2023 | +0.4% | -3.0% | -12.9% | |
| Q3 2023 | -6.0% | -9.0% | -26.1% | |
| Q2 2023 | +0.0% | +3.5% | +11.9% | |
| Q1 2023 | -4.3% | -2.2% | +11.4% | |
| Q4 2022 | -1.7% | -6.1% | -9.6% | |
| Q3 2022 | -13.9% | -22.2% | +5.6% | |
| Q2 2022 | -6.3% | -5.9% | -15.1% | |
| Q1 2022 | -3.9% | +1.0% | +1.9% | |
| Q4 2021 | +4.6% | -4.6% | +19.8% | |
| Q3 2021 | -1.4% | -3.4% | -14.9% | |
| Q2 2021 | -2.5% | -4.8% | +7.8% | |
| Q1 2021 | +0.6% | -3.2% | +23.6% | |
| Q4 2020 | -11.4% | -4.9% | -20.5% | |
| Q3 2020 | +2.9% | +0.0% | +0.0% | |
| Q2 2020 | -2.1% | -2.1% | -27.7% | |
| Q1 2020 | +13.5% | +6.8% | -24.3% | |
| Q4 2019 | -22.0% | -35.4% | -18.3% | |
| Q3 2019 | -26.3% | -33.8% | -31.6% | |
| Q2 2019 | -19.9% | -18.0% | -11.4% | |
| Q1 2019 | -19.4% | -24.3% | -14.4% | |
| Q4 2018 | -10.0% | -12.5% | -46.6% | |
| Q3 2018 | -4.2% | -8.3% | -20.8% | |
| Q2 2018 | +4.8% | +4.8% | -9.5% | |
| Q1 2018 | +7.3% | -2.4% | -7.3% | |
| Q4 2017 | -1.0% | -0.8% | -41.2% | |
| Q3 2017 | +0.0% | +2.6% | -64.1% | |
| Q2 2017 | -6.3% | -16.7% | -33.3% | |
| Q1 2017 | +0.0% | -7.9% | -12.7% | |
| Q4 2016 | -9.0% | -14.5% | -59.0% | |
| Q3 2016 | -4.1% | +2.4% | +22.9% | |
| Q2 2016 | -10.5% | -15.8% | -31.6% | |
| Q1 2016 | -14.3% | — | — | |
| Q4 2015 | +2.0% | — | — | |
| Q3 2015 | -15.8% | — | — | |
| Q2 2015 | -25.0% | — | — | |
| Q1 2015 | -11.5% | — | — | |
| Q4 2014 | +15.4% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +2.1% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +2.0% | — | — | |
| Q3 2013 | -3.1% | — | — | |
| Q2 2013 | -0.9% | — | — | |
| Q1 2013 | -6.0% | — | — | |
| Q4 2012 | -8.6% | — | — | |
| Q3 2012 | +1.4% | — | — | |
| Q2 2012 | +2.1% | — | — | |
| Q1 2012 | -16.8% | — | — | |
| Q4 2011 | +9.7% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +7.7% | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro